Chase Medical Research, LLC | Waterbury, MA
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this is study is to compare the efficacy of BHV-3500 (zavegepant) to placebo as a preventive treatment for migraine, as measured by the reduction in the number of migraine days per month.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Subject has at least 1 year history of migraine (with or without aura) consistent with a diagnosis according to the International Classification of
Headache Disorders, 3rd Edition, including the following:
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
538 participants in 4 patient groups, including a placebo group
Loading...
Central trial contact
Pfizer CT.gov Call Center
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal